Researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen ...

Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast ...

Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...

U.S. Urology Partners is one of the first providers to offer patients ImmunityBio’s recombinant Bacillus Calmette-Guérin (rBCG) The FDA recently authorized ImmunityBio’s EAP for rBCG to address U.S.

ImmunityBio (IBRX) announced U.S. Urology Partners, one of the nation’s largest independent providers of urology and related specialty ...

ImmunityBio (IBRX) faces operational, financial, and competitive challenges, impacting its growth prospects despite Anktiva's ...

You may think of vaccines as a way to prevent disease, but researchers are testing a new kind that might help treat breast cancer. It works by activating the immune system-- your body's defense ...

Studying Up: Navigating Bladder Cancer Treatment Mike makes informed decisions ... His treatment began with six weeks of BCG therapy, a procedure where a modified version of the tuberculosis vaccine ...

When BCG therapy was combined with chemotherapy and administered at lower doses, fewer treatment-related symptoms and side effects were reported by patients with NMIBC, compared to other BCG ...

"The results [indicate] that neoadjuvant DV combined with toripalimab had promising efficacy and acceptable safety in patients with HER2-expressing MIBC,” said Xinan Sheng, MD. The pCR was 37.3% (95% ...

Remarkably, the only approved vaccine for TB is the century-old Bacillus Calmette-Guerin (BCG) vaccine. This vaccine contains a weakened form of the Mycobacterium bovis bacteria, which is closely ...